A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-26 and is reviewed periodically as new material appears.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
==== CRISPR RNA ==== Archaea also have systems of regulatory RNA. The CRISPR system, recently being used to edit DNA in situ, acts via regulatory RNAs in archaea and bacteria to provide protection against virus invaders.
== Products and promotions == TCBY offers frozen yogurt in a variety of flavors. The chain typically serves hard scooped and soft serve yogurt, while newer concept stores only offer soft serve. The new concept stores follow a self-service model, with customers being charged by weight. Soft serve yogurt comes in Golden Vanilla, Chocolate, and White Chocolate Mousse flavors, in addition to various rotating flavors. TCBY also serves drinks such as Berriyo yogurt smoothies and Frappe Chillers. In September 2010, TCBY announced the test launch of breakfast and lunch meal replacement bowls, parfaits and smoothies made from non-frozen "fresh" yogurt called Yovana-Simply Yogurt in two self-service company stores in its headquarters of Salt Lake City. 2010 also saw the opening of a prototype store in Salt Lake City, operating under a different business model. Instead of customers ordering and being served in a traditional fashion, they serve themselves using any combination of available yogurt flavors, add their own mix of fruit or candy toppings, and pay by the ounce. In May 2011, TCBY launched Super Fro-Yo, a reformulated version of its yogurt with a more nutrient-rich profile. The company brought down the fat content of its yogurt to below 2 percent, so it can be labeled low fat. On January 10, 2012, TCBY launched a Greek frozen yogurt product. TCBY is the first frozen yogurt chain to offer Greek frozen yogurt. Every year, TCBY offers mothers across the nation a free frozen yogurt on Mother's Day, and fathers a free frozen yogurt on Father's Day.
== Risks == As with any procedure, there are risks involved; these include reactions to medicine, problems breathing, bleeding, and infection. Infection is reported to occur in less than 1% of cases and is curable with antibiotics. Overall, patients with a preexisting illness are at a higher risk of getting an infection as opposed to those who are overall healthy.
=== Verdicts and sentencing === Final verdicts were delivered on 18 August 2023. Letby was found guilty of seven counts of murder and seven counts of attempted murder relating to six further infants. Eleven of the convictions were reached by a 10–1 majority, while the verdicts concerning Children F, L and O were unanimous. She was acquitted on two counts of attempted murder, and the jury was unable to reach verdicts on six additional attempted murder charges. The prosecution requested 28 days to consider whether to seek a retrial on those counts.
Sources: en.wikipedia.org
=== Off-label drugs === α2-Adrenergic receptor antagonists (e.g., yohimbine, rauwolscine (found in yohimbe)) – erectile dysfunction, low sexual desire Androgens/anabolic steroids (androgen receptor agonists) (e.g., testosterone, testosterone esters, methyltestosterone) – low sexual desire Antiandrogens (e.g., GnRH modulators, high-dose estrogen therapy, high-dose progestogen therapy) – various mechanisms of action – paraphilias, hypersexuality, sexual deviance Antipsychotics (e.g., haloperidol) – dopamine receptor antagonists, other actions – paraphilias, hypersexuality, sexual deviance Bupropion (Wellbutrin, Zyban) – norepinephrine–dopamine reuptake inhibitor (NDRI), other actions – low sexual desire Buspirone (Buspar) – serotonin 5-HT1A receptor agonist, other actions – low sexual desire Clomipramine (Anafranil) – tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions – premature ejaculation Cyproheptadine (Periactin) – non-selective serotonin receptor antagonist, other actions – anorgasmia, low sexual desire/decreased libido Estrogens (e.g., estradiol, estradiol esters, ethinylestradiol) – estrogens (estrogen receptor agonists) – atrophic vaginitis, dyspareunia, vulvodynia, low sexual desire Horny goat weed (Epimedii herba) – unknown mechanism of action – low sexual desire Selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluoxetine, paroxetine, citalopram, escitalopram) – premature ejaculation, paraphilias, hypersexuality, sexual deviance Selegiline (L-deprenyl; Eldepryl, Zelapar, Emsam) – monoamine oxidase B (MAO-B) inhibitor, other actions – low sexual desire Tramadol (Tramal) – μ-opioid receptor agonist, serotonin–norepinephrine reuptake inhibitor (SNRI), other actions – premature ejaculation Trazodone (Desyrel, Oleptro) – serotonin antagonist and reuptake inhibitor (SARI), various actions – erectile dysfunction, low sexual desire
The two substrates of this enzyme are dihydrophloroglucinol (1) and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are phloroglucinol (2), reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is dihydrophloroglucinol:NADP+ oxidoreductase. This enzyme participates in benzoate degradation via CoA ligation.
==== Solid forms ==== For its main use as a fertilizer urea is mostly marketed in solid form, either as prills or granules. Prills are solidified droplets, whose production predates satisfactory urea granulation processes. Prills can be produced more cheaply than granules, but the limited size of prills (up to about 2.1 mm (0.083 in) in diameter), their low crushing strength, and the caking or crushing of prills during bulk storage and handling make them inferior to granules. Granules are produced by accretion onto urea seed particles by spraying liquid urea in a succession of layers. Formaldehyde is added during the production of both prills and granules in order to increase crushing strength and suppress caking. Other shaping techniques such as pastillization (depositing uniform-sized liquid droplets onto a cooling conveyor belt) are also used.
is the dimensionality of the system. Examples include charge-charge interactions between ions and dipole-dipole interactions between molecules. Modelling these forces presents quite a challenge as they are significant over a distance which may be larger than half the box length with simulations of many thousands of particles. Though one solution would be to significantly increase the size of the box length, this brute force approach is less than ideal as the simulation would become computationally very expensive. Spherically truncating the potential is also out of the question as unrealistic behaviour may be observed when the distance is close to the cut off distance. The most important long-range interactions are electrostatic interactions between two (partly) charge atoms. At present, the most used method is Particle Mesh Ewald (PME). PME uses Ewald summations to split the calculations into a short- and long range part. The short-range part calculates all interactions within a cut-off range, the long-range part is solved in reciprocal space, using fast Fourier transforms (FFTs). The high accuracy and high calculation speed made PME the gold standard for many years. However the increase use of parallelization, PME runs into a communication bottleneck because the FFTs require an all-to-all communication. A attractive PME alternative are the fast multipole methods (FMM), which are not affected by an increase in parallelization.
== T == Koichi Tanaka (born 1959), Japanese electrical engineer, 2002 Nobel Prize in Chemistry Henry Taube (1915–2005), American chemist, (1983 Nobel Prize in Chemistry Louis Jacques Thénard (1777–1857), French chemist, discovered hydrogen peroxide and Thenard's Blue Sir Harold Warris Thompson (1908–1983), English physical chemist J. J. Thomson (1856–1940), British physicist, Known in chemistry for discovery of isotopes T. Don Tilley (born 1954), organometallic chemist Arne Tiselius (1902–1971), Swedish biochemist, 1948 Nobel Prize in Chemistry Max Tishler (1906–1989), American chemist, 1970 Priestley Medal Alexander R. Todd, Baron Todd (1907–1997), British biochemist, 1957 Nobel Prize in Chemistry Evangelista Torricelli (1608–1647), Italian physicist and chemist, invented the barometer, pupil of Galileo Roger Y. Tsien (1952–2016), American biochemist, 2008 Nobel Prize in Chemistry Mikhail Tsvet (1872–1919), Russian botanist, known for adsorption chromatography Kristy Turner, British chemist
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.